search
Back to results

Markers of Vascular Aging and Coronary Syndrome (MAVASCOR)

Primary Purpose

Acute Coronary Syndrome

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
blood sample withdrawn
Sponsored by
CHU de Reims
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Acute Coronary Syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • acute coronary heart syndrome
  • included during hospitalization, usual cardiologic follow-up planned in Reims university hospital

Exclusion Criteria:

  • <18yo

Sites / Locations

  • Chu Reims

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

acute coronary syndrome

Arm Description

Outcomes

Primary Outcome Measures

Post-translational modifications of Proteins quantification assessed by Liquid chromatography-mass spectrometry

Secondary Outcome Measures

Full Information

First Posted
July 29, 2016
Last Updated
October 24, 2018
Sponsor
CHU de Reims
search

1. Study Identification

Unique Protocol Identification Number
NCT02857387
Brief Title
Markers of Vascular Aging and Coronary Syndrome
Acronym
MAVASCOR
Official Title
Markers of Vascular Aging and Coronary Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
October 2015 (Actual)
Primary Completion Date
August 27, 2018 (Actual)
Study Completion Date
August 27, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CHU de Reims

4. Oversight

5. Study Description

Brief Summary
Atherosclerosis and aging are associated to the raise of biochemical alterations of proteins grouped under the name of " non-enzymatic post-translational modifications ". They often correspond to the irreversible binding of glucose or other oses (glycation) or urea derivatives (carbamylation) on proteins and lead to the formation of complex compounds (post-translational modifications derived products, PTMD) that can accumulate in tissues and be responsible for deleterious effects. The specific role of these compounds in the pathophysiology of aging and atherosclerosis remains unknown, as are the molecular and cellular mechanisms implicated. This project is based on the hypothesis that non-enzymatic post-translational modifications may cause changes in the genesis of complication of coronary atherosclerosis and that PTMD could therefore constitute relevant biomarkers in this specific clinical situation. To explore these potential new biomarkers, the investigators designed a study in patients having experienced an acute coronary syndrome and followed during a year. The concentrations of PTMD assayed at 0, 1, 3, 12 months, will be correlated to clinical (severity and evolution) and paraclinical (cutaneous autofluorescence) data and the effect of cardiac rehabilitation will be assessed. This should help to identify new (and non-traditional) biomarkers of coronary heart disease and determine some of the implicated pathophysiological mechanisms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
65 (Actual)

8. Arms, Groups, and Interventions

Arm Title
acute coronary syndrome
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
blood sample withdrawn
Primary Outcome Measure Information:
Title
Post-translational modifications of Proteins quantification assessed by Liquid chromatography-mass spectrometry
Time Frame
up to 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: acute coronary heart syndrome included during hospitalization, usual cardiologic follow-up planned in Reims university hospital Exclusion Criteria: <18yo
Facility Information:
Facility Name
Chu Reims
City
France
State/Province
Reims
ZIP/Postal Code
51092
Country
France

12. IPD Sharing Statement

Learn more about this trial

Markers of Vascular Aging and Coronary Syndrome

We'll reach out to this number within 24 hrs